Company intelligence / Profile preview

Medera Inc.

Boston, MA, United Statesmadera.gov ↗

Ownership: Public · KVAC
Development stage: Phase 2

Overview

Medera has three ongoing AAV-based cardiac gene therapy clinical trials. SRD-002 for HFpEF has demonstrated promising Phase 1/2 efficacy and safety, with plans to initiate a pivotal trial by the end of 2025. SRD-001 for HFrEF is in Phase 1/2 trials with completion expected in Q4 2025. SRD-003 for DMD-CM is in Phase 1/2 trials with interim data expected in mid-2026. The company has received Fast Track Designation for its HFpEF program and Orphan Drug Designation for its DMD-CM program.

Therapeutic areas: PulmonologyCardiovascular
Modalities: Gene therapyCell therapySmall molecules
Industry: Biotech

Drug pipeline

7 assets

MBD-001

Preclinical

6 more assets in the full pipeline.

Request access →

Partnerships

AstraZeneca

Financials

Market cap: $106.3M
Total revenue: $0
Enterprise value: $106.3M

Beyond the preview

Go deeper on Medera Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medera Inc..

Explore the full profile